Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-05-26 Major Shareholding Noti…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by Morgan Stanley in Alligator Bioscience AB. It explicitly mentions 'Gränsvärde för antal aktier' (Threshold for number of shares), 'Andel' (Share/Percentage), and provides a breakdown of direct and indirect holdings, culminating in a total percentage (5.98723%). This structure is characteristic of a notification regarding a change in significant share ownership, often referred to as a 'flagging notification' in Nordic regulatory contexts. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is short and specific, not a full annual report or earnings release.
2025-05-26 Swedish
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document details a change in shareholding percentage (from an unspecified amount before the transaction to 2.41295% after) by a specific holder (Avanza Bank Holding AB for Avanza Pension) in Alligator Bioscience AB. It explicitly mentions 'Gränsvärde för antal aktier' (Threshold for number of shares) being 5% and that the threshold was crossed due to 'Aktielån' (Stock lending). This structure—reporting current holdings, previous holdings (even if missing), the transaction reason, and the resulting percentage relative to a threshold—is characteristic of a Major Shareholding Notification, often mandated by financial supervisory authorities (like the Swedish FI mentioned in the footnotes) when ownership crosses specific percentage limits (e.g., 5%). This aligns perfectly with the definition for Major Shareholding Notification (MRQ).
2025-05-23 Swedish
Alligator Bioscience AB announces final outcome of exercise of warrants series TO 12
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ALLIGATOR BIOSCIENCE AB ANNOUNCES FINAL OUTCOME OF EXERCISE OF WARRANTS SERIES TO 12". It details the results of a warrant exercise program, including the number of shares subscribed, the resulting capital raised (SEK 51.5 million from exercised warrants, plus expected SEK 10.0 million from guarantee execution), the resulting dilution, and subsequent share capital changes. It also mentions future actions like a directed issue to guarantors and repayment of a loan. This content directly relates to changes in the company's capital structure and financing activities resulting from the exercise of securities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific financing event outcome.
2025-05-21 English
Alligator Bioscience AB meddelar slutligt utfall för nyttjandet av teckningsoptioner serie TO 12
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "ALLIGATOR BIOSCIENCE AB MEDDELAR SLUTLIGT UTFALL FÖR NYTTJANDET AV TECKNINGSOPTIONER SERIE TO 12" (Alligator Bioscience AB announces final outcome for the exercise of warrants series TO 12). It details the results of a warrant exercise period, including the utilization rate (71%), the number of shares subscribed, the resulting capital increase, and the subsequent actions regarding guarantee commitments (top guarantee). This announcement concerns a specific corporate action related to capital structure and financing activities following a previous rights issue. This fits best under the 'Capital/Financing Update' category (CAP). Although it announces the outcome of a financing event, it is a detailed announcement, not just a brief notice of publication, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule, as the core content is the financial outcome itself.
2025-05-21 Swedish
Alligator Bioscience AB meddelar preliminärt utfall för nyttjandet av teckningsoptioner serie TO 12
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience AB announcing the preliminary outcome of the exercise of warrants (teckningsoptioner serie TO 12). It details the number of warrants exercised, the resulting new shares, the preliminary proceeds (MSEK), and the impact on associated top guarantee commitments. This type of announcement, which reports on the completion or outcome of a financing/capital event (warrant exercise), fits best under 'Capital/Financing Update' (CAP). Although it relates to capital structure, it is a specific announcement about the result of a prior financing mechanism (warrant exercise), rather than a general update on fundraising activities (CAP) or a notice of a dividend (DIV). Since it is a specific announcement about the result of a capital instrument exercise, CAP is the most appropriate fit among the provided options, as it directly concerns capital structure changes resulting from the exercise. It is not a full report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific corporate action update.
2025-05-20 Swedish
Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 12
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ALLIGATOR BIOSCIENCE AB ANNOUNCES PRELIMINARY OUTCOME OF EXERCISE OF WARRANTS SERIES TO 12". It details the preliminary results of a warrant exercise, including the number of warrants exercised, shares subscribed for, and the resulting capital raised (SEK 51.5 million). This announcement concerns a financing/capital structure event (the exercise of warrants issued during a Rights Issue). This fits best under the Capital/Financing Update category (CAP). Although it is a press release, its core subject matter is financing, making CAP more specific than the general Regulatory Filings (RNS) or Report Publication Announcement (RPA). The document is not a full report, but a specific announcement about a capital event.
2025-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.